Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COL17A1 encoding stem cell therapy - Holostem Terapie Avanzate

Next Previous
Search
Drug Profile

COL17A1 encoding stem cell therapy - Holostem Terapie Avanzate

Alternative Names: Hologene 17; HOLOGENE-17

Latest Information Update: 31 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Holostem Terapie Avanzate
  • Developer Holostem Terapie Avanzate; Paracelsus Medical University
  • Class Cell therapies; Gene therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Collagen type XVII replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Epidermolysis bullosa

Most Recent Events

  • 18 Mar 2021 Phase-I/II development is ongoing in Epidermolysis bullosa (In adolescents, In adults, In children) in Austria (Parenteral)
  • 11 Sep 2018 Holostem Terapie Avanzate in collaboration with Paracelsus Medical University terminates the phase I/II HOLOGENE17 trial in Epidermolysis bullosa (In children, In adolescents, In adults) in Austria (Parenteral) (NCT03490331)
  • 19 Mar 2018 Phase-I/II clinical trials in Epidermolysis bullosa (In children, In adolescents, In adults) in Austria (Parenteral) (NCT03490331)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top